Dr. Reddy’s Laboratories announced the launch of Paricalcitol Capsules, the generic version of AbbVie’s Zemplar.

Zemplar is an active form of vitamin D used to prevent and treat secondary hyperparathyroidism in patients with Stage 3 or Stage 4 chronic kidney disease and in Stage 5 patients on dialysis. The biological effects of paricalcitol are mediated through binding of the vitamin D receptor, which results in the selective activation of the vitamin D responsive pathways. Vitamin D and paricalcitol have been shown to reduce parathyroid hormone levels by inhibiting parathyroid hormone synthesis and secretion.

RELATED: Generic Zemplar Capsules Available from Teva

Paricalcitol Capsules are available in 1mcg, 2mcg, and 4mcg strengths in 30-count bottles.

For more information call (866) 733-3952 or visit DrReddys.com.